西安2021年8月17日 /美通社/ -- 西安天美生物科技股份有限公司（納斯達(dá)克代碼：BON））（“天美生物”或“公司”），一家在天然、健康和個人護(hù)理行業(yè)提供關(guān)鍵活性成分及解決方案的領(lǐng)先供應(yīng)商，今天宣布其截至2021年3月31日的6個月的半年度財務(wù)業(yè)績。
2021年上半年財務(wù)亮點(diǎn)
管理層討論
“我們創(chuàng)新高的收入和收益的加速增長是我們作為上市公司首次公布業(yè)績的很好的答卷，并為天美作為上市公司起了一個良好的開端，”天美生物的董事長兼CEO胡永衛(wèi)表示，“我們的行業(yè)知名品牌與優(yōu)質(zhì)產(chǎn)品相結(jié)合，為我們的客戶帶來了很高的價值主張，并為我們在這個市場需求增長的時期提升市場份額提供了堅實(shí)的基礎(chǔ)。今年到目前為止，我們在新業(yè)務(wù)上取得的成果以及正在開發(fā)中的產(chǎn)品銷售的趨勢也令我感到鼓舞。我們將繼續(xù)優(yōu)化我們的銷售策略，著重大型企業(yè)客戶，并降低我們的制造成本，以支持可持續(xù)的長期盈利能力。我要感謝我們辛勤工作的團(tuán)隊(duì)，公司的成功離不開他們的不懈努力，以及我們忠實(shí)的客戶對我們的信任。我們在玉門工廠的擴(kuò)張的時機(jī)非常好。目前，市場對我們產(chǎn)品需求旺盛，產(chǎn)能的提升提高，將為公司銷售增長提供保障，更好滿足當(dāng)前市場客戶的需求。而公司新生產(chǎn)基地可以幫助我們實(shí)現(xiàn)這一目標(biāo)。我們相信，我們的獨(dú)有的技術(shù)、商業(yè)模式和戰(zhàn)略將使我們能夠獲得更多的市場份額，并保持增長勢頭?！?/p>
2021上半年產(chǎn)品（按類別）與上年相比增長總結(jié)：
收入增加（減少） |
毛利潤增加（減少） |
|
香料原料 |
133.0% |
226.9% |
膳食補(bǔ)充劑（固體飲料） |
338.4% |
306.0% |
生物活性食品原料 |
(69.7%) |
(79.0%) |
香料原料
膳食補(bǔ)充劑（固體飲料）
生物活性食品原料
管理費(fèi)用從截至2020年3月31日的六個月的811,799美元減少到2021年同期的679,635美元，減少了132,164美元，或大約16.3%，主要是由于截至2021年3月31日的六個月內(nèi)專業(yè)咨詢服務(wù)費(fèi)用減少了197,327美元。公司在截至2020年3月31日的六個月內(nèi)產(chǎn)生了較高的咨詢服務(wù)費(fèi)用和較高的審計費(fèi)用。
政府補(bǔ)貼以補(bǔ)貼形式獲得并確認(rèn)為其他營業(yè)收入，在截至2021年3月31日和2020年3月31日的六個月里，總額分別為446,910美元和332,418美元。
凈利潤從截至2020年3月31日的六個月的160萬美元增加到2021年同期的230萬美元。
經(jīng)營活動產(chǎn)生的凈現(xiàn)金在截至2021年3月31日的六個月期間為200萬美元，2020年同期為50萬美元。
稀釋后每股收益（“EPS”）為0.40美元，2020年同期為0.30美元。
我們鼓勵投資者查閱公司完整的財務(wù)報表和相關(guān)的披露資料，以了解更多信息。這些材料可在https://www.sec.gov/edgar/browse/?CIK=1816815&owner=exclude.中查閱。
報告期后事件
投資者電話會議和網(wǎng)絡(luò)直播
討論公司2021年上半年財務(wù)業(yè)績的網(wǎng)絡(luò)直播將于2021年8月17日美國東部時間上午8:30開始。網(wǎng)絡(luò)直播和相關(guān)PPT的獲取可以訪問公司的投資者網(wǎng)站 https://ir.bnlus.com/events-presentations/。對于無法觀看網(wǎng)絡(luò)直播的人，在活動結(jié)束后公司將在網(wǎng)站上提供錄制版本。
預(yù)先登記：https://dpregister.com/sreg/10159604/ec6c783af0
預(yù)先登記的呼叫者將得到一個會議密碼和獨(dú)有PIN碼，可以立即進(jìn)入電話會議并繞過接線員。與會者可以在任何時候進(jìn)行預(yù)先登記，包括在電話會議開始后。
無法互聯(lián)網(wǎng)接入或無法預(yù)先登記的人可以通過以下電話撥入：
美國免費(fèi)電話：1-866-777-2509
國際收費(fèi)電話：1-412-317-5413
西安天美生物科技股份有限公司
西安天美生物專注于膳食營養(yǎng)補(bǔ)充劑的生物活性成分的生產(chǎn)，如為食品制造商提供天然益生元；個人護(hù)理成分的生產(chǎn)，如為香水香料制造商提供從植物來源的香料原料，天然復(fù)配膳食補(bǔ)充劑生產(chǎn)，如固體飲料。欲了解更多信息，請訪問公司網(wǎng)站：www.bnlus.com.
安全港聲明
本新聞稿包含了1995年《私人證券訴訟改革法案》中的前瞻性聲明。前瞻性聲明包括了有關(guān)公司計劃、目標(biāo)、戰(zhàn)略、未來事件或業(yè)績的聲明，以及其他假設(shè)和不包含歷史事件的聲明。當(dāng)公司使用諸如“可能”、“將”、“打算”、“應(yīng)該”、“相信”、“期望”、“預(yù)期”、“計劃”、“估計”等或其他類似的表達(dá)方式，并不與歷史事件有關(guān)，就是在做前瞻性聲明。前瞻性聲明不是對公司未來業(yè)績的保證，涉及風(fēng)險和不確定性，可能會導(dǎo)致實(shí)際結(jié)果與前瞻性聲明中討論的公司預(yù)期有實(shí)質(zhì)性的差異。這些陳述受不確定性和風(fēng)險因素的印象，包括但不限于：公司的目標(biāo)和戰(zhàn)略、公司的未來業(yè)務(wù)發(fā)展、公司產(chǎn)品和服務(wù)的需求、技術(shù)的變化、經(jīng)濟(jì)狀況、中國天然健康和個人護(hù)理行業(yè)的發(fā)展及公司希望發(fā)展的其他國際市場、聲譽(yù)和品牌、競爭和定價的影響、政府法規(guī)、中國及公司希望發(fā)展的其他國際市場的經(jīng)濟(jì)和商業(yè)狀況的變動，以及與上述任何情況相關(guān)的假設(shè)和公司提交給SEC報告中所陳述的其他風(fēng)險。因此，我們提醒投資者不要過分依賴本新聞稿中的前瞻性陳述。公司向SEC提交的文件中討論了其他因素，這些文件可在www.sec.gov 上查閱。公司不承擔(dān)公開修訂本聲明日期之后出現(xiàn)的事件或情況的前瞻性聲明的義務(wù)。
更多信息，請聯(lián)系：
In the United States: |
In China: |
Maggie Zhang | Impact IR |
Sophie Zhang | Impact IR |
Phone: (646) 893-8916 |
Email: sophie.zhang@irimpact.com |
Email: maggie.zhang@irimpact.com |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(UNAUDITED) |
||||||||
As of |
||||||||
March 31, 2021 |
September 30, 2020 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS |
||||||||
Cash |
$ |
1,040,607 |
$ |
53,106 |
||||
Accounts receivable, net |
8,869,747 |
5,771,008 |
||||||
Inventories, net |
1,446,516 |
1,016,442 |
||||||
Advance to suppliers, net |
1,894,359 |
3,491,145 |
||||||
Deferred initial public offering costs |
984,162 |
510,079 |
||||||
Prepaid expenses and other current assets |
106,786 |
7,434 |
||||||
TOTAL CURRENT ASSETS |
14,342,177 |
10,840,214 |
||||||
Property, plant and equipment, net |
14,590,470 |
14,171,963 |
||||||
Intangible assets, net |
144,126 |
140,993 |
||||||
Right-of-use lease assets, net |
229,532 |
|||||||
Deferred tax assets, net |
37,032 |
49,059 |
||||||
TOTAL ASSETS |
$ |
29,343,337 |
$ |
25,202,229 |
||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
CURRENT LIABILITIES |
||||||||
Short-term loans |
$ |
1,823,215 |
$ |
1,289,081 |
||||
Current portion of long-term loans |
2,318,528 |
1,227,346 |
||||||
Third party loans |
- |
690,327 |
||||||
Accounts payable |
577,311 |
1,288,629 |
||||||
Due to related parties |
1,019,128 |
2,322,990 |
||||||
Taxes payable |
5,688,786 |
4,402,625 |
||||||
Accrued expenses and other current liabilities |
1,275,936 |
442,582 |
||||||
Finance lease liabilities, current |
148,983 |
33,389 |
||||||
Operating lease liability, current |
57,051 |
|||||||
TOTAL CURRENT LIABILITIES |
$ |
12,908,938 |
$ |
11,696,969 |
||||
Long-term loans |
2,106,180 |
2,482,251 |
||||||
Finance lease liabilities, noncurrent |
110,499 |
- |
||||||
Operating lease liability, noncurrent |
176,701 |
- |
||||||
TOTAL LIABILITIES |
15,302,318 |
14,179,220 |
||||||
COMMITMENTS AND CONTINGENCIES EQUITY |
||||||||
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, |
$ |
580 |
$ |
580 |
||||
Additional paid in capital |
5,567,873 |
5,251,205 |
||||||
Statutory reserve |
579,922 |
579,922 |
||||||
Retained earnings |
7,384,071 |
5,072,672 |
||||||
Accumulated other comprehensive income (loss) |
15,421 |
(388,102) |
||||||
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY |
13,547,867 |
10,516,277 |
||||||
Non-controlling interest |
493,152 |
506,732 |
||||||
Total equity |
14,041,019 |
11,023,009 |
||||||
TOTAL LIABILITIES AND EQUITY |
$ |
29,343,337 |
$ |
25,202,229 |
||||
*Retrospectively restated for effect of 1-for-3 shares reverse split. |
||||||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME |
||||||||
(UNAUDITED) |
||||||||
For the six months ended March 31, |
||||||||
2021 |
2020 |
|||||||
REVENUE |
$ |
11,698,830 |
$ |
7,149,785 |
||||
COST OF REVENUE |
(8,325,148) |
(4,597,617) |
||||||
GROSS PROFIT |
3,373,682 |
2,552,168 |
||||||
OPERATING EXPENSES |
||||||||
Selling expenses |
(52,666) |
(59,765) |
||||||
General and administrative expenses |
(679,635) |
(811,799) |
||||||
Research and development expenses |
(106,998) |
(128,481) |
||||||
Total operating expenses |
(839,299) |
(1,000,045) |
||||||
INCOME FROM OPERATIONS |
2,534,383 |
1,552,123 |
||||||
OTHER INCOME (EXPENSES) |
||||||||
Interest income |
294 |
451 |
||||||
Interest expense |
(197,168) |
(172,913) |
||||||
Unrealized foreign transaction exchange gain (loss) |
(65,691) |
(4,300) |
||||||
Government subsidies |
446,910 |
332,418 |
||||||
Other income |
41,548 |
136,482 |
||||||
Total other income (expenses) |
225,893 |
292,138 |
||||||
INCOME BEFORE INCOME TAX PROVISION |
2,760,276 |
1,844,261 |
||||||
INCOME TAX PROVISION |
(465,077) |
(249,766) |
||||||
NET INCOME |
2,295,199 |
1,594,495 |
||||||
Less: net income (loss) attributable to non-controlling interest |
(16,200) |
61,317 |
||||||
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED |
2,311,399 |
1,533,178 |
||||||
OTHER COMPREHENSIVE INCOME (LOSS) |
||||||||
Total foreign currency translation adjustment |
406,143 |
32,468 |
||||||
TOTAL COMPREHENSIVE INCOME |
2,701,342 |
1,626,963 |
||||||
Less: comprehensive income (loss) attributable to non-controlling |
(13,580) |
59,939 |
||||||
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON |
$ |
2,714,922 |
$ |
1,567,024 |
||||
EARNINGS PER SHARE |
||||||||
Basic and diluted |
$ |
0.40 |
$ |
0.30 |
||||
WEIGHTED AVERAGE NUMBER OF SHARES |
||||||||
Basic and diluted* |
5,800,000 |
5,166,667 |
||||||
* Retrospectively restated for effect of reverse split.
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(UNAUDITED) |
||||||||
For the six months ended March 31, |
||||||||
2021 |
2020 |
|||||||
Cash flows from operating activities |
||||||||
Net income |
$ |
2,295,199 |
$ |
1,594,495 |
||||
Adjustments to reconcile net income to cash provided by operating |
||||||||
Allowance for doubtful accounts |
6,323 |
23,316 |
||||||
Depreciation and amortization |
117,888 |
134,457 |
||||||
Deferred income tax |
13,879 |
(19,459) |
||||||
Amortization of operating lease right-of-use assets |
26,195 |
- |
||||||
Unrealized foreign currency exchange loss |
65,691 |
4,300 |
||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(2,898,493) |
(410,656) |
||||||
Inventories |
(391,958) |
482,914 |
||||||
Advance to suppliers |
1,738,442 |
(1,787,999) |
||||||
Prepaid expenses and other current assets |
(99,108) |
17,251 |
||||||
Accounts payable |
(760,103) |
(809,818) |
||||||
Operating lease liabilities |
(21,975) |
- |
||||||
Taxes payable |
1,120,847 |
905,514 |
||||||
Accrued expenses and other current liabilities |
786,942 |
412,845 |
||||||
Net cash provided by operating activities |
1,999,769 |
547,160 |
||||||
Cash flows from investing activities |
||||||||
Purchase of property and equipment |
(715) |
(26,957) |
||||||
Capital expenditures on construction-in-progress |
- |
(403,911) |
||||||
Net cash used in investing activities |
(715) |
(430,868) |
||||||
Cash flows from financing activities |
||||||||
Proceeds from short-term loans |
943,517 |
601,833 |
||||||
Proceeds from long-term loans |
685,067 |
41,001 |
||||||
Repayment of short-term loans |
(457,729) |
(1,211,475) |
||||||
Repayment of long-term loans |
(109,382) |
- |
||||||
Proceeds from (repayment of) borrowings from related parties |
(1,391,813) |
393,367 |
||||||
Proceeds from (repayment of) third party loans |
(716,574) |
76,797 |
||||||
Principal payment from (repayment of) finance lease |
254,970 |
(195,863) |
||||||
Payment for deferred initial public offering costs |
(155,557) |
(42,705) |
||||||
Net cash used in financing activities |
(947,501) |
(337,045) |
||||||
Effect of changes of foreign exchange rates on cash |
(64,052) |
15,605 |
||||||
Net increase (decrease) in cash |
987,501 |
(205,148) |
||||||
Cash, beginning of year |
53,106 |
293,771 |
||||||
Cash, end of year |
$ |
1,040,607 |
$ |
88,623 |
||||
Supplemental disclosure of cash flow information |
||||||||
Cash paid for interest expense |
$ |
215,268 |
$ |
172,913 |
||||
Cash paid for income tax |
$ |
1,424 |
$ |
- |
||||
Supplemental disclosure of non-cash investing and financing activities |
||||||||
Amortization of share-based compensation for initial public offering |
$ |
316,668 |
$ |
- |
||||
Right-of-use assets obtained in exchange for operating lease |
255,811 |
- |
||||||
